Видео ютуба по тегу Decitabine

Phase I/II study of a quizartinib, venetoclax, & decitabine triplet regimen in FLT3-ITD mutated AML
Phase I/II study of a quizartinib, venetoclax, & decitabine triplet regimen in FLT3-ITD mutated AML
Clip Decitabine
Clip Decitabine
APA ITU OBAT DECITABINE?
APA ITU OBAT DECITABINE?
Risk-adapted therapy: three-day versus five-day oral decitabine in patients with MDS
Risk-adapted therapy: three-day versus five-day oral decitabine in patients with MDS
The all-oral regimen of decitabine/cedazuridine, venetoclax, & gilteritinib for older pts with AML
The all-oral regimen of decitabine/cedazuridine, venetoclax, & gilteritinib for older pts with AML
ASCO24 Updates: 7+3 vs Decitabine and Venetoclax: Which Treatment is Superior for Elderly Patients?
ASCO24 Updates: 7+3 vs Decitabine and Venetoclax: Which Treatment is Superior for Elderly Patients?
Synergistic Effects of HDAC, PARP Inhibitors, and Decitabine in Pancreatic Cancer | Oncotarget
Synergistic Effects of HDAC, PARP Inhibitors, and Decitabine in Pancreatic Cancer | Oncotarget
Race Oncology's breakthrough in cancer cell treatment
Race Oncology's breakthrough in cancer cell treatment
Acute Myeloid Leukemia, Myledodysplastic Syndrome, Dacogen, Decitabine, Venetoclax, Venclexta,
Acute Myeloid Leukemia, Myledodysplastic Syndrome, Dacogen, Decitabine, Venetoclax, Venclexta,
24 - Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with AML
24 - Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with AML
Quizartinib, venetoclax, and decitabine in patients with FLT3-ITD AML: a Phase I/II trial
Quizartinib, venetoclax, and decitabine in patients with FLT3-ITD AML: a Phase I/II trial
Optimizing HMA treatment in HR-MDS: azacitidine versus decitabine
Optimizing HMA treatment in HR-MDS: azacitidine versus decitabine
Decitabine, venetoclax, and IDH inhibitor in IDH-mutated AML
Decitabine, venetoclax, and IDH inhibitor in IDH-mutated AML
INQOVI (decitabine and cedazuridine)- myelodysplastic syndromes
INQOVI (decitabine and cedazuridine)- myelodysplastic syndromes
Oral combination of ASTX727 (decitabine/cedazuridine) plus Ven for older/unfit patients with AML
Oral combination of ASTX727 (decitabine/cedazuridine) plus Ven for older/unfit patients with AML
10-day ASTX727 (decitabine/cedazuridine) with venetoclax in the treatment of R/R AML
10-day ASTX727 (decitabine/cedazuridine) with venetoclax in the treatment of R/R AML
MPN Researcher Discusses ASH 2023 Highlights
MPN Researcher Discusses ASH 2023 Highlights